KCC2 maintains the correct levels of chloride ions in neurons, playing a major part in regulating excitation and inhibition of neurons. The results indicate that a genetic mutation of KCC2 might be a risk factor for developing IGE.
“We found a clear statistical association between two variants of KCC2 and severe IGE in a large French-Canadian patient sample,” said Dr. Guy Rouleau, Director of the Montreal Neurological Institute and Hospital-The Neuro, at McGill University and the McGill University Health Centre, and senior author of the study. “Our data not only corroborate recent findings by other groups but vastly extend them from genetic, physiological and biochemical standpoints.” The first authors on the paper are Dr. Kristopher Kahle, chief neurosurgery resident at Massachusetts General Hospital and post-doctoral fellow at Harvard University, and Dr. Nancy Merner, a former post-doctoral fellow in Dr. Rouleau’s laboratory and now a professor at Auburn University.
The study examined 380 French Canadians with IGE living in Montreal and Quebec City. Results were compared to data from a control group of more than 1,200 people. “KCC2 is a hot topic in neuroscience given its important role in neuronal signaling and in its potential role in neurological diseases such as epilepsy, neuropathic pain, and other diseases,” said Dr. Rouleau.
Each day in Canada, an average of 42 people learn that they have epilepsy. In 50 – 60% of cases, the cause of epilepsy is unknown. The major form of treatment is long-term drug therapy. Drugs are not a cure and can have numerous, sometimes severe, side effects. Brain surgery is recommended only when medication fails and when the seizures are confined to one area of the brain where brain tissue can be safely removed without damaging personality or function.
The Neuro has been at the forefront of epilepsy treatment and research for over half a century. The “Montreal Procedure” developed at The Neuro revolutionized the surgical treatment for epilepsy. The use of EEG and MRI for the study and treatment of epilepsy was also pioneered at The Neuro. The Neuro’s Epilepsy Program has a multi-disciplinary team of epileptologists, neurosurgeons, nurses, neuropsychologists, neuropsychiatrists, social workers, EEG technologists, nurse clinicians and case managers. The Program provides both in-patient and out-patient evaluation and treatments for more than 3000 patients a year and the EEG Clinic conducts almost 4,000 electroencephalograms each year.
Researchers at The Neuro collaborated in this study with scientists at leading institutions in the USA, France, and the U.K. as well as with scientists at the Centre of Research and the Department of Medicine at the Université de Montréal.
To read the full article in EMBO Reports:http://embor.embopress.org/content/early/2014/06/10/embr.201438840
The Neuro: The Montreal Neurological Institute and Hospital – The Neuro, is a unique academic medical centre dedicated to neuroscience. A research and teaching institute of McGill University, The Neuro forms the basis for the Neuroscience Mission of the McGill University Health Centre. Founded in 1934 by Dr. Wilder Penfield, The Neuro is recognized internationally for integrating research, compassionate patient care and advanced training, all key to advances in science and medicine. Neuro researchers are world leaders in cellular and molecular neuroscience, brain imaging, cognitive neuroscience and the study and treatment of epilepsy, multiple sclerosis and neuromuscular disorders. For more information, please visit www.theneuro.com